8-K: Exagen Inc. Reports Improved Financial Results for Third Quarter 2024, Driven by Increased Average Selling Price

Exagen Inc. announced its third quarter 2024 results, highlighting a 26% increase in the average selling price of its AVISE CTD test and reduced adjusted EBITDA losses.

Summary

• Exagen Inc. reported a revenue of $12.5 million for the third quarter of 2024, which included a negative impact of $1.2 million from one-time adjustments.
• Excluding these adjustments, revenue was in line with expectations.
• The trailing twelve-month average selling price (ASP) for AVISE CTD increased by 26% to $404 compared to the same period in 2023.
• The net loss for the first three quarters of 2024 improved by $6.8 million, or 37%, compared to the same period in 2023.
• The adjusted EBITDA loss for the first three quarters of 2024 improved by $5.6 million, or 42%, compared to the same period in 2023.
• Cash and cash equivalents stood at $22.0 million as of September 30, 2024, with a net cash burn of $2.5 million for the quarter.
• The company completed analytical validation for new biomarkers to enhance AVISE CTD and submitted them for approval to the NY State Department of Health.
• Exagen has updated its full-year 2024 revenue guidance to $55 million to $56 million, primarily due to the one-time adjustments in Q3, and reiterated its adjusted EBITDA loss expectations of better than $12 million.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with significant improvements in key financial metrics and product development. However, the negative impact of one-time adjustments and the ongoing losses temper the overall sentiment.

Positives

• The average selling price of AVISE CTD has significantly increased, indicating strong market demand and pricing power.
• The company has made substantial progress in reducing its net loss and adjusted EBITDA loss year-over-year.
• Exagen has a solid cash position of $22 million, providing a financial cushion for operations and growth.
• The completion of analytical validation for new biomarkers and submission for approval demonstrates ongoing innovation and product development.
• The company has reiterated its adjusted EBITDA loss expectations for the full year, indicating confidence in its financial management.

Negatives

• The third quarter revenue was negatively impacted by $1.2 million in one-time adjustments.
• The gross margin for the third quarter of 2024 was 55.8%, down from 57.4% in the same quarter of 2023, partly due to one-time adjustments.
• The company experienced a net loss of $5.0 million in the third quarter of 2024, although this is an improvement from the $5.4 million loss in the same quarter of 2023.
• Adjusted EBITDA loss was $4.0 million in the third quarter of 2024, compared to a $3.6 million loss in the third quarter of 2023.

Risks

• The company's financial performance is subject to fluctuations due to one-time adjustments.
• The company's ability to achieve profitability depends on continued revenue growth and cost management.
• The company's success is dependent on obtaining and maintaining market acceptance of its testing products.
• Delays in reimbursement and coverage decisions from Medicare and third-party payors could impact revenue.
• Regulatory developments and changes in laws could affect the company's business.

Future Outlook

The company expects full-year 2024 revenue of $55 million to $56 million and reiterates adjusted EBITDA loss expectations of better than $12 million.

Management Comments

• We've positioned ourselves for a strong finish to 2024 and laid the groundwork for an exciting 2025, as we look to add new proprietary biomarkers to enhance our flagship product, AVISE CTD.
• We remain prudent with our cash as we drive towards profitable growth and continue to shape Exagen as an industry leader in novel autoimmune testing.
• This is the perfect time to have Jeff join our leadership team and I welcome him as we deliver on the potential that lies ahead, said John Aballi, President and Chief Executive Officer.

Industry Context

Exagen operates in the autoimmune diagnostics market, which is characterized by a need for accurate and timely testing solutions. The company's focus on innovative biomarkers and its flagship product, AVISE CTD, positions it to compete effectively in this space. The increase in ASP suggests a strong market demand for their products.

Comparison to Industry Standards

• Exagen's 26% increase in ASP for AVISE CTD is a strong indicator of market acceptance and pricing power, which is a key metric for diagnostic companies.
• Compared to companies like Myriad Genetics or Exact Sciences, which also focus on specialized testing, Exagen's focus on autoimmune diseases provides a niche market.
• The improvement in net loss and adjusted EBITDA loss suggests that Exagen is making progress towards profitability, which is a common goal for companies in the diagnostic sector.
• The company's cash burn of $2.5 million for the quarter is relatively low compared to other biotech companies in the development stage, indicating efficient cash management.

Management Changes

Stakeholder Impact

• Shareholders will likely view the improved financial results and increased ASP positively.
• Employees may be encouraged by the company's progress and future outlook.
• Customers (physicians and patients) will benefit from the enhanced AVISE CTD test with new biomarkers.
• Suppliers and creditors may see the company as a more stable and reliable partner due to its improved financial position.

Next Steps

• The company plans to add new proprietary biomarkers to enhance its flagship product, AVISE CTD.
• Exagen will continue to focus on driving towards profitable growth.
• The company will host a conference call to review the third quarter 2024 financial results and provide a business update.

Key Dates

Keywords

autoimmune testing, AVISE CTD, diagnostics, revenue, EBITDA, biomarkers, financial results, net loss, ASP, Exagen